GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Principia Biopharma Inc (NAS:PRNB) » Definitions » Revenue per Share

Principia Biopharma (Principia Biopharma) Revenue per Share : $1.42 (TTM As of Jun. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Principia Biopharma Revenue per Share?

Principia Biopharma's revenue per share for the three months ended in Jun. 2020 was $1.42. Principia Biopharma's revenue per share for the trailing twelve months (TTM) ended in Jun. 2020 was $1.42.

During the past 12 months, the average Revenue Per Share Growth Rate of Principia Biopharma was -73.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Principia Biopharma's Revenue per Share or its related term are showing as below:

PRNB's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.7
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Principia Biopharma Revenue per Share Historical Data

The historical data trend for Principia Biopharma's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Principia Biopharma Revenue per Share Chart

Principia Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Revenue per Share
- 0.38 8.01 1.36

Principia Biopharma Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 - - - 1.42

Competitive Comparison of Principia Biopharma's Revenue per Share

For the Biotechnology subindustry, Principia Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Principia Biopharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Principia Biopharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Principia Biopharma's PS Ratio falls into.



Principia Biopharma Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Principia Biopharma's Revenue Per Share for the fiscal year that ended in Dec. 2019 is calculated as

Revenue Per Share (A: Dec. 2019 )=Revenue (A: Dec. 2019 )/Shares Outstanding (Diluted Average) (A: Dec. 2019 )
=35.16/25.778
=1.36

Principia Biopharma's Revenue Per Share for the quarter that ended in Jun. 2020 is calculated as

Revenue Per Share (Q: Jun. 2020 )=Revenue (Q: Jun. 2020 )/Shares Outstanding (Diluted Average) (Q: Jun. 2020 )
=50/35.312
=1.42

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Principia Biopharma  (NAS:PRNB) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Principia Biopharma Revenue per Share Related Terms

Thank you for viewing the detailed overview of Principia Biopharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Principia Biopharma (Principia Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
220 East Grand Avenue, South San Francisco, CA, USA, 94080
Principia Biopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapies for immunology and oncology. Its proprietary Tailored Covalency platform enables to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities. The company pipeline products include PRN1008 and PRN2246 and PRN1371 under BTK franchise.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Stefani Wolff officer: Chief Development Officer C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Martin Babler director, officer: President, CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Dolca Thomas officer: Chief Medical Officer C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
Shao-lee Lin director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
David M Goldstein officer: Chief Scientific Officer C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080
Roy C. Hardiman officer: Chief Business Officer C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Christopher Y Chai officer: Chief Financial Officer 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Principia Biopharma (Principia Biopharma) Headlines